【摘 要】
：
Hepatocellular carcinoma (HCC) is one of the leading caus-es of cancer deaths worldwide and liver transplantation (LT) is the only potentially curative treatment. Over the years, Milan criteria has been used for patient selection. There is ongoing researc
【机 构】
：
Department of Internal Medicine,Greater Baltimore Medical Center,MD,USA;Department of Internal Medic
论文部分内容阅读
Hepatocellular carcinoma (HCC) is one of the leading caus-es of cancer deaths worldwide and liver transplantation (LT) is the only potentially curative treatment. Over the years, Milan criteria has been used for patient selection. There is ongoing research in this field with introduction of new biomarkers for HCC that can help guide future treat-ment. Furthermore, newer therapies for downstaging of the tumor are being implemented to prevent dropout from the transplant list. In addition, combination therapies for better outcome are under investigation. Interestingly, the concept of living-donor LT and possible use of hepatitis C virus-positive donors has been implemented as an attempt to expand the organ pool. However, there is a conflict of opinion between different centers regarding its efficacy and data is scarce. The aim of this review article is to outline the various selection criteria for LT, discuss the outcomes of LT in HCC patients, and explore future directions of LT for HCC. Therefore, a comprehensive PubMed/MEDLINE review was conducted. To expand our search, references of the retrieved articles were also screened for additional data. After selecting the studies, the authors independent-ly reviewed them to identify the relevant studies. After careful evaluation 120 studies relevant to out topic are cited in the manuscript. Three tables and two figures are also included. In conclusion LT for HCC has evolved over the years. With the introduction of several expanded cri-teria beyond Milan, the introduction of bridging therapies, such as transcatheter arterial chemoembolization and radi-ofrequency ablation, and the approval of newer systemic therapies, it is evident that there will be more LT recipients in the future. It is promising to see ongoing trials and the continuous evolution of protocols. Prospective studies are needed to guide the development of a pre-LT criteria that can ensure low HCC recurrence risk and is not overly strin- gent, clarify the role of LDLT, and determine the optimal bridging therapies to LT.
其他文献
Background and Aims: Endovascular implantation of io-dine-125 (125I) seeds strand combined with stent is an effec-tive method of treatment for portal vein tumor thrombosis. The aim of this study was to develop a novel endovascular brachytherapy stent (EVB
Background and Aims: Acute liver failure (ALF) is an inflam-matory process of acute liver cell injury. Mesenchymal stem cells (MSCs) are undifferentiated, primitive cells with anti-inflammatory, anti-apoptotic, and multi-directional differen-tiation abili
The diagnosis of metabolic-associated fatty liver disease is based on the detection of liver steatosis together with the presence of metabolic dysfunction. According to this new defi-nition, the diagnosis of metabolic-associated fatty liver disease is ind
Nonalcoholic fatty liver disease (NAFLD) affects about a quar-ter of the world\'s population and poses a major health and economic burden globally. Recently, there have been hasty attempts to rename NAFLD to metabolic-associated fatty liv-er disease (MA
Metabolic dysfunction-associated fatty liver disease (com-monly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and eco-nomic burden is enormous. While much attention has been given to metabolic syndro
Background and Aims: The efficacy of targeted pro-grammed cell death 1/programmed death ligand 1 (PD-1/PD-L1) monoclonal antibodies (mAbs) has been confirmed in many solid malignant tumors. The overexpression of PD-1/PD-L1 serves as a biomarker to predict
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is currently the most common chronic liver disease and affects at least a quarter of the global adult population. It has rapidly become one of the leading causes of hepa-tocellular carcinoma a
Background and Aims: Exertional heatstroke (EHS) is as-sociated with strenuous physical activity in hot environments. The present study aimed to investigate dynamic changes of hepatic function indices in EHS patients and determine risk factors for death.
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new term from nonalcoholic fatty liver disease (NAFLD) and is a positive diagnosis based on histopathology, imaging, or blood biomarkers. MAFLD is one of the common causes of liver dysfunct
Hepatic encephalopathy is an often devastating complication of chronic liver disease, associated with high mortality and in-creased burden on patients and healthcare systems. Current agents (such as nonabsorbable disaccharides and oral anti-biotics) are o